Bactria Pharmaceuticals LLC
The University of Colorado Connection
Bactria Pharmaceuticals is a Boulder-based biotechnology company dedicated to combating antibiotic resistance in Gram-negative bacterial pathogens. The company was co-founded by Corrie Detweiler (CU Boulder Department of Molecular, Cellular & Developmental Biology). Bactria's scientific foundation stems from Detweiler's research, particularly the development of the SAFIRE (Screen for Anti-infectives using Fluorescence microscopy of Intracellular Enterobacteriaceae) platform, which identifies small molecules that disrupt bacterial infections by targeting efflux pumps and compromising bacterial membranes. By leveraging these discoveries, Bactria aims to develop novel small-molecule therapeutics that restore the efficacy of existing antibiotics against multidrug-resistant healthcare-associated infections.
Funding Status and Investment Opportunities
- Industry Applications: Biotech, Therapeutics
- Funding Round: Seed
- Contact for Investment Inquiries: cmorl@bactriarx.com
Venture Partners Programs
- Bioscience Discovery and Evaluation Grant Program (now Lab Venture Challenge) (2010)
- Intellectual Property Management (2008)
Technology Development Funding
U.S. National Institutes of Health (NIH), Colorado Office of Economic Development and International Trade (OEDIT)
This page was last updated on April 17, 2026. Please email vpnews@colorado.edu for corrections or updates
The Insider eNewsletter
Media Inquiries
For marketing inquiries and news tips, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.